M2DS Therapeutics, Inc.

M2DS Therapeutics is developing therapies for genetic neurodevelopmental disorders caused by gene duplication. The Company has licensed a novel brain delivery technology as well as a targeted siRNA sequence from the RNA Therapeutics Institute at the UMass Chan School of Medicine (home to multiple Nobel Laureates), and as its first program is developing a novel therapy (MDS-1764) for MECP2 Duplication Syndrome, a rare disease caused by the overproduction of the MECP2 protein (the opposite of Rett Syndrome). M2DS plans to expand the use of the amphiphilic conjugate (dendrimer) technology to other diseases in or controlled by the brain.